ANIK Anika Therapeutics Inc.

Anika to Participate in Upcoming Virtual Investor Conferences

Anika to Participate in Upcoming Virtual Investor Conferences

BEDFORD, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following three virtual investor conferences in May:

  • The 16th Annual Canaccord Genuity Musculoskeletal Conference on Thursday, May 20, 2021 will host a live presentation starting at 9:00 a.m. ET.
  • The UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 will host a live presentation starting at 8:00 a.m. ET.
  • Oppenheimer’s MedTech, Tools & Diagnostics Summit will post a pre-recorded presentation on Wednesday, May 26, 2021.

Webcasts of all events will be available in the  section of Anika’s website, . An audio archive of the all the presentations will also be available on the website.

About Anika

(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Anika is headquartered in Massachusetts with operations in the United States and Europe. For more information about Anika, please visit

For Investor Inquiries:

Mark Namaroff

Anika Therapeutics, Inc.

Executive Director, Investor Relations and Corporate Communications

Direct: 781-457-9287



EN
04/05/2021

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May ...

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024 BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (toll-free domestic) or 1-416-764-8658 (i...

April 18, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Con...

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET. Webcast of the presentation and Q&A will be available in the  section of Anika’s website, . An archive of the presentation will also be available on the website. About Anika...

April 2, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Anika Reports Fourth Quarter and Year-End 2023 Financial Results Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preserva...

March 13, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the A...

March 8, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on W...

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024 BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (toll-fr...

February 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch